SCHEMBL14387083

SCHEMBL14387083

COc1ccc(C2CCN(CC(O)C3(O)CCN(C(=S)Nc4cc(OC)cc(OC)c4)CC3)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ RAB9A P51151 2/20 0.46
▸ GAA P10253 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ LMNA P02545 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ LHCGR P22888 1/20 0.41
▸ DRD2 P14416 1/20 0.41
▸ CYP3A4 P08684 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14430086 0.92 KMT2A (0.45) KMT2AMEN1RAB9AGAAKDM4E
SCHEMBL14386850 0.89 MEN1 (0.46) KMT2AMEN1RAB9AGAANPC1
SCHEMBL14386902 0.85 KMT2A (0.53) KMT2AMEN1RAB9AGAAKDM4E
SCHEMBL5328461 0.85 DRD2 (0.47) KMT2AMEN1RAB9ANPC1LMNA
SCHEMBL14386847 0.81 S1PR2 (0.48) GAANPC1ALDH1A1CYP3A4
SCHEMBL5322032 0.81 DRD2 (0.47) RAB9ALMNAALDH1A1DRD2
SCHEMBL5328459 0.80 DRD2 (0.46) RAB9ALMNAALDH1A1DRD2CYP3A4
SCHEMBL14430094 0.79 LMNA (0.45) KMT2AMEN1RAB9ANPC1LMNA
SCHEMBL14386855 0.78 MAPT (0.49) KMT2AMEN1RAB9ANPC1LMNA
SCHEMBL14386852 0.78 MCHR1 (0.47) KMT2AGAASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007130712-A1 SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES JANSSEN PHARMACEUTICA, NV (BE) 2007-11-15 — — WO disclosed
US-20070197590-A1 SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS JANSSEN PHARMACEUTCA N.V. (BE) 2007-08-23 — — US disclosed
US-20070197590-A1 SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS JANSSEN PHARMACEUTCA N.V. (BE) 2007-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197590-A1 SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS CCR2, CCR1, CCR5 KMT2A 2990/4885MEN1 4602/4885RAB9A 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback